MARKET WIREReuters • 59m ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
Why CSBR Stock Traded Steady Today — RQD Quant Desk Flash
$4.81 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.80
Champions Oncology Inc. (CSBR) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $66.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CSBR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CSBR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Champions Oncology Inc. (NASDAQ: CSBR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $4.81 (0.00% 1D, market cap $66.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CSBR ranks #975 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CSBR compare to CGTX and GRML in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CSBR carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 48.0%, and ROIC of -26.9%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and GRML (Greenland Mines Ltd.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, CSBR leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CSBR?
▼
Per CSBR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000771856), Champions Oncology Inc. generated $59.4M in revenue (+4.4% YoY), -$1.2K in net income, and -$5.0M in free cash flow against $28.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.80 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-16.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CSBR)Realized 20D OHLCV Swing Band: ±8.4%
Deterministic 5-Pillar Attribution (22/100 Composite)
🔍 WHY CSBR SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (32% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (27% of score)
20D Institutional Volume Accumulation (±8.4% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.84-2.9% Next Q
30
Q2 (-2Q)Grade E$4.70+0.4% Next Q
27
Q3 (-1Q)Grade E$4.72+1.9% Next Q
25
CurrentGrade E$4.81-11.4% Hist 90D α
22
Trajectory: E (30) → E (22)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CSBR Turnaround Squeeze
While CSBR currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.95) and Max Pain ($5.05) forces dealer call-delta covering toward $8.73.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CSBR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CSBR Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CSBR Stock Traded Steady Today — RQD Quant Desk Flash
Champions Oncology Inc. (CSBR) slipped 0.00% to $4.81, trading at 6% of its 52-week range ($4.59 – $8.31). Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 6% of its 52-week range ($4.59 – $8.31) with RSI-14 at 46.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.4% around $4.81 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 48% gross margin and $0 annual free cash flow.
Live CSBR Headlines & Catalysts
MARKET WIREReuters • 1h ago
China's foreign minister pushes for dialogue to resolve Middle East conflict - ReutersChina's foreign minister pushes for dialogue to resolve Middle East conflict Reuters
MARKET WIREReuters • 3h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 4h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 5h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 6h ago
Gold rebounds from one-year low as oil slides ahead of US midterms - ReutersGold rebounds from one-year low as oil slides ahead of US midterms Reuters
MARKET WIREReuters • 7h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
MARKET WIREReuters • 8h ago
Reliance earnings, lower oil prices power India's Sensex to near two-month high - ReutersReliance earnings, lower oil prices power India's Sensex to near two-month high Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CSBR)
- ✓Walkthrough of CSBR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CSBR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.30%▼ DESCENDING CHANNEL
2026-10-30O $4.86H $4.95L $4.76C $4.81VOL 8.4K
RES: $5.09SUP: $4.22SMA50: $4.95SMA200: $5.75
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CSBR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +4.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CSBR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CSBR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CSBR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CSBR)
Health Care Rank #975 of 1016
⚔️ CGTX vs CSBR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CSBR vs. CGTX, GRML, PTHS, CRDF)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Champions Oncology Inc. (CSBR) ranks #975 by composite RQD confidence (22/100, grade E) and #714 by equity capitalization ($66.9M). Within this direct 5-issuer industry benchmark cohort, CSBR leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with CSBR at 22/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CSBR
ACTIVE
Champions Oncology Inc. | E | 22/100 | — | 48.0% | -26.9% | 0.00% | $66.9M | Benchmark Subject |
| CGTX Cognition Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -5.57% | $70.3M | /cgtx-vs-csbr → |
| GRML Greenland Mines Ltd. | E | 32/100 | — | — | -35.0% | -10.89% | $70.3M | /grml-vs-csbr → |
| PTHS Pelthos Therapeutics Inc. | E | 34/100 | — | 76.3% | -35.0% | -43.17% | $63.3M | /pths-vs-csbr → |
| CRDF Cardiff Oncology Inc. | D- | 41/100 | — | — | -35.0% | -2.46% | $70.9M | /crdf-vs-csbr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0000771856In its most recent audited fiscal period (FY2025, filed 2026-04-30), Champions Oncology Inc. (CSBR) reported GAAP revenue of $59.4M (+4.4% vs. FY2024 revenue of $56.9M , and +18.5% cumulative change since FY2023) , GAAP net income of -$1.2K, operating cash flow of -$4.5M, and free cash flow of -$5.0M (-172.0% YoY). On the balance sheet, CSBR closed FY2025 with $28.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-04-30 | $59.4M | -$1.2K | -$4.5M | -$5.0M | $28.4M | — |
| FY2024 (FY) | 2025-04-30 | $56.9M | $4.7K | $7.4M | $7.0M | $30.6M | — |
| FY2023 (FY) | 2024-04-30 | $50.2M | -$7.3K | -$6.1M | -$6.1M | — | — |
3. CSBR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CSBR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Champions Oncology Inc. (NASDAQ: CSBR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $4.81 (0.00% 1D, market cap $66.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CSBR ranks #975 in composite RQD confidence.
How does CSBR compare to CGTX and GRML in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CSBR carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 48.0%, and ROIC of -26.9%. By comparison, CGTX (Cognition Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M) and GRML (Greenland Mines Ltd.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, CSBR leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CSBR?
Per CSBR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000771856), Champions Oncology Inc. generated $59.4M in revenue (+4.4% YoY), -$1.2K in net income, and -$5.0M in free cash flow against $28.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CSBR trading relative to its 50-day, 200-day, and 52-week technical levels?
CSBR last traded at $4.81 (0.00% on volume of 8,439 shares), positioning the stock -2.83% below its 50-day simple moving average ($4.95) and -16.35% below its 200-day simple moving average ($5.75). Across its 52-week range of $4.59 to $8.31, CSBR sits at the 5.9% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.4% ($4.41 to $5.21).
CSBR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CSBR stock moving today?
Why CSBR Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.